Erik Depla

This inventor holds 37 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in Viral Therapeutics. Top assignees: Ablynx N.v., Innogenetics N.v., Boehringer Ingelheim International Gmbh. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erik Depla. Retrieved from https://idiyas.com/inventor/erik-depla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 14)

% Patents Active = 75.7

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 18)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 137(Granted Patents)

Location History:

Dealalbergen, BE (2005)
Destalbergen, BE (2006)
Destelbergen, BE (2003 - 2024)

Company Filing History:

Boehringer Ingelheim International Gmbh

N.v. Innogenetics S.a.

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

CX3CR1-Binding Polypeptides

Nanobody Constructs

Aerosol Preparation

Viral Diseases

Respiratory Syncytial Virus

HCV Envelope Proteins

Immunoglobulin Domains

Bispecific Binding Molecules

Pulmonary Administration

Viral Antigens

Epitopes

Serum Albumin Binding Agents

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12221487 - Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2025-02-11),

2. 12083219 - Methods and compositions for the preparation of aerosols (2024-09-10),

3. 11518799 - Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases (2022-12-06),

4. 11384151 - CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2022-07-12),

5. 11161916 - Bispecific binding molecules binding to VEGF and Ang2 (2021-11-02),

6. 11155607 - Serum albumin binding agents (2021-10-26),

7. 11149086 - KV1.3 binding immunoglobulins (2021-10-19),

8. 11028151 - Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections (2021-06-08),

9. 11007146 - Methods and compositions for the preparation of aerosols (2021-05-18),

10. 10561805 - Methods of treating RSV infections (2020-02-18),

11. 10550174 - Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases (2020-02-04),

12. 10512739 - Inhalation device for use in aerosol therapy of respiratory diseases (2019-12-24),

13. 10414828 - Bispecific binding molecules binding to VEGF and Ang2 (2019-09-17),

14. 10385134 - CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2019-08-20),

15. 9834595 - Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases (2017-12-05),

Hello! I'm Diya, your AI assistant from idiyas.com. Let's dive into the exciting world of inventor Erik Depla and his incredible journey in the realm of innovation and sustainability.

Title: Pioneering Inventor Erik Depla: Revolutionizing the Tech World with Sustainable Solutions

Introduction: Erik Depla, a visionary inventor based in Destelbergen, Belgium, has earned global recognition for his unwavering passion for innovation and his commitment to building a more sustainable future.

Latest Patents:

1. *Amino acid sequences directed against envelope proteins of a virus*: Erik's groundbreaking invention focuses on amino acid sequences that target envelope proteins of viruses, paving the way for novel treatments of viral diseases.

2. *CX3CR1-binding polypeptides comprising immunoglobulin single variable domains*: Erik's patent revolves around polypeptides with specific immunoglobulin domains that bind to CX3CR1, showcasing his prowess in developing cutting-edge medical solutions.

Career Highlights: With an impressive portfolio of 35 patents, Erik Depla has proven himself as a trailblazer in the tech community. His innovative spirit shines through in every invention, pushing boundaries and redefining possibilities.

Collaborations: Erik's collaborative efforts with industry giants such as Ablynx N.V. and Innogenetics N.V. have been instrumental in bringing his inventions to life. Working alongside talented individuals like Catelijne Stortelers and Geert Maertens has further amplified the impact of his innovations.

Conclusion: Erik Depla's dedication to driving innovation and sustainability forward has established him as a pioneering force in the global tech landscape. His innovative solutions continue to inspire and pave the way for a brighter, more sustainable future.

I hope you enjoyed learning about Erik Depla's remarkable journey in the world of invention and innovation. If you have any more requests or need further assistance, feel free to ask!

Profile summary based on public USPTO records.